We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NRC Health's Q1 Earnings Fall Y/Y Due to Elevated Operating Costs
Read MoreHide Full Article
NRC Health (NRC - Free Report) reported first-quarter 2026 adjusted earnings per share of 21 cents, which declined from 26 cents last year.
Revenues of $34.8 million represented a 4% increase from $33.6 million in the prior-year period.
Net income, however, declined to $3.2 million from $5.8 million a year ago, marking a decrease of roughly 44%.
The results reflect modest top-line growth but pressure on profitability, even as the company returned to year-over-year revenue expansion after a period of stagnation.
Other Key Business Metrics
A standout metric in the quarter was Total Recurring Contract Value (TRCV), which rose 13% year over year to $152.1 million, marking the sixth consecutive quarter of sequential growth and signaling strengthening demand visibility. Cash flow from operations increased 8% to $7.2 million, while free cash flow surged to $5.4 million from $3.7 million a year earlier, reflecting improved cash generation. Adjusted EBITDA came in at $9.4 million, though the margin declined to 27% from 30.8% in the prior-year quarter due to higher operating expenses.
Management Commentary
Management emphasized momentum in both sales and customer retention, highlighted by the signing of the largest deal in the company’s history. According to CEO Trent Green, this milestone validates NRC Health’s strategy and underscores its ability to deliver measurable outcomes for healthcare systems. The company also reported multi-year highs in new sales and retention rates, suggesting strengthening customer engagement and trust.
Leadership is focused on expanding from a measurement-centric approach to one centered on driving actionable outcomes. Management noted that investments in product enhancements and broader solution integration are helping deepen customer relationships and expand use cases.
Factors Influencing Performance
Profitability was impacted by increased operating costs, particularly in selling, general and administrative expenses, which rose significantly year over year. Management attributed margin pressure to investments in executive team expansion, corporate expenses, and stock-based compensation, as well as the timing mismatch between TRCV growth and revenue recognition.
Additionally, the company cited implementation timelines for large, multi-phase deals as a near-term constraint on revenue realization. Sizable contracts — such as the recently signed landmark agreement — are expected to contribute to revenues over multiple years, with phased rollouts influencing the timing of financial impact.
Guidance and Outlook
Management expressed confidence in continued growth, supported by a strong pipeline and expanding product capabilities. The company expects margins to improve over time as revenue catches up with TRCV and implementation costs associated with large deals normalize. Management also indicated that adjusted EBITDA margins could expand sequentially in the second half of the year as rollout expenses taper.
Other Developments
During the quarter, NRC Health continued its shareholder return initiatives, declaring a quarterly dividend of 16 cents per share and executing share repurchases. Additionally, management highlighted a newly authorized $60 million share repurchase program, signaling confidence in the company’s long-term value and commitment to capital allocation discipline.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
NRC Health's Q1 Earnings Fall Y/Y Due to Elevated Operating Costs
NRC Health (NRC - Free Report) reported first-quarter 2026 adjusted earnings per share of 21 cents, which declined from 26 cents last year.
Revenues of $34.8 million represented a 4% increase from $33.6 million in the prior-year period.
Net income, however, declined to $3.2 million from $5.8 million a year ago, marking a decrease of roughly 44%.
The results reflect modest top-line growth but pressure on profitability, even as the company returned to year-over-year revenue expansion after a period of stagnation.
Other Key Business Metrics
A standout metric in the quarter was Total Recurring Contract Value (TRCV), which rose 13% year over year to $152.1 million, marking the sixth consecutive quarter of sequential growth and signaling strengthening demand visibility. Cash flow from operations increased 8% to $7.2 million, while free cash flow surged to $5.4 million from $3.7 million a year earlier, reflecting improved cash generation. Adjusted EBITDA came in at $9.4 million, though the margin declined to 27% from 30.8% in the prior-year quarter due to higher operating expenses.
Management Commentary
Management emphasized momentum in both sales and customer retention, highlighted by the signing of the largest deal in the company’s history. According to CEO Trent Green, this milestone validates NRC Health’s strategy and underscores its ability to deliver measurable outcomes for healthcare systems. The company also reported multi-year highs in new sales and retention rates, suggesting strengthening customer engagement and trust.
Leadership is focused on expanding from a measurement-centric approach to one centered on driving actionable outcomes. Management noted that investments in product enhancements and broader solution integration are helping deepen customer relationships and expand use cases.
Factors Influencing Performance
Profitability was impacted by increased operating costs, particularly in selling, general and administrative expenses, which rose significantly year over year. Management attributed margin pressure to investments in executive team expansion, corporate expenses, and stock-based compensation, as well as the timing mismatch between TRCV growth and revenue recognition.
Additionally, the company cited implementation timelines for large, multi-phase deals as a near-term constraint on revenue realization. Sizable contracts — such as the recently signed landmark agreement — are expected to contribute to revenues over multiple years, with phased rollouts influencing the timing of financial impact.
Guidance and Outlook
Management expressed confidence in continued growth, supported by a strong pipeline and expanding product capabilities. The company expects margins to improve over time as revenue catches up with TRCV and implementation costs associated with large deals normalize. Management also indicated that adjusted EBITDA margins could expand sequentially in the second half of the year as rollout expenses taper.
Other Developments
During the quarter, NRC Health continued its shareholder return initiatives, declaring a quarterly dividend of 16 cents per share and executing share repurchases. Additionally, management highlighted a newly authorized $60 million share repurchase program, signaling confidence in the company’s long-term value and commitment to capital allocation discipline.